/PRNewswire/ Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced positive interim.
Zanidatamab generated responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer who were previously treated with gemcitabine.
/PRNewswire/ Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, will be presenting positive.
Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period Launched BRUKINSA in the U.S. for adult patients with chronic lymphocytic
Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period
Launched BRUKINSA® in the U.S. for adult patients with chronic. | May 4, 2023